INTARCIA ANNOUNCES INTERIM RESULTS FROM HCV STUDY

Intarcia Therapeutics has announced interim results from a Phase II study of omega interferon with or without ribavirin in interferon-naive Genotype 1 chronic HCV patients. The results demonstrate that omega interferon in combination with ribavirin is well-tolerated and shows robust antiviral activity as evidenced by an early viral response rate of 84 percent.

This study of daily subcutaneous omega interferon injections is providing Intarcia with safety and clinical response data in support of further development of omega interferon delivered by continuous release from the DUROS device.

Omega interferon is a naturally occurring, human, glycosylated, Type 1 interferon manufactured by recombinant technology, with a serum half-life of approximately nine to 15 hours. Omega DUROS is a product designed to deliver a continuous and consistent dose of omega interferon for three months via the small DUROS device after a single subcutaneous insertion in the upper arm.